The latest clinical research progress of pemetinib/pemetinib

Pemigatinib is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3. After showing certain efficacy in the treatment of cholangiocarcinoma in recent years, researchers are actively exploring its potential role in other solid tumors carrying FGFR alterations. One of the high-profile studies is FIGHT-209, a phase 2 clinical trial designed to evaluate pemetinib in relapsed or refractory gliomas harboring FGFR1-3 gene alterations, particularly glioblastoma. This research provides a new direction for molecularly targeted treatment of brain malignant tumors and is also considered to be a highly exploratory attempt in the field of neuro-oncology.

The core of the FIGHT-209 study is to verify whether pemetinib can penetrate the blood-brain barrier in the brain and produce an effective inhibitory effect on tumor cells carrying FGFR gene abnormalities. A major difficulty in the treatment of brain tumors is that many systemic therapeutic drugs cannot effectively penetrate the blood-brain barrier, and FGFR abnormalities found in some gliomas may be closely related to tumor proliferation, self-renewal, and resistance to radiotherapy and chemotherapy. This study enrolled patients with clear genetic backgrounds and comprehensively evaluated the safety, brain activity, tolerability and clinical response of pemetinib in the central nervous system.

Judging from the currently published results,FIGHT-209 shows that pemetinib has shown certain clinical benefits in some patients, especially in some patients with low-grade astrocytoma or pleomorphic xanthoastrocytoma (PXA) with FGFR1 or FGFR3 gene alterations. A trend of stable or even shrinking disease was observed. However, in patients with glioblastoma (GBM), the efficacy is relatively limited, which may be related to the high heterogeneity, rapid progression and complex immune microenvironment of glioblastoma. Despite this, there are still individual GBM patients in the study who show more sensitive individual responses to FGFR inhibition, suggesting that this strategy is still valuable in specific subtypes.

In addition, the study also conducted an in-depth analysis of the pharmacokinetic performance of pemetinib in the brain and the dynamic changes of related biomarkers, providing a scientific basis for subsequent screening of suitable populations. Although the overall objective response rate (ORR) has not yet reached the breakthrough treatment standard, FIGHT-209 provides a basis for future combination treatments. For example, whether FGFR inhibitors can be combined with immunotherapy, radiotherapy or PI3K/AKT inhibitors to enhance the overall therapeutic effect has become a hot topic in subsequent research.

It is worth noting that the study also revealed that some patients experienced typical targeted side effects after using pemetinib, such as hyperphosphatemia, stomatitis and fatigue, which are similar to its spectrum of adverse reactions in other tumor types, indicating that the safety of pemetinib in the nervous system is generally controllable. The researchers also recommend maintaining treatment compliance through individualized dose adjustment, early identification of side effects, and discontinuation of treatment when necessary.

Overall,Although FIGHT-209 is still in the exploratory stage, its results are of great significance in expanding the boundaries of targeted drugs in the treatment of central nervous system tumors. It not only verifies the feasibility of FGFR as a potential therapeutic target for some gliomas, but also promotes the practical application of precision treatment concepts in the field of neuro-oncology.

Reference materials:https://go.drugbank.com/drugs/DB15102